Skin Cancer pp 75-88 | Cite as

Basal Cell Carcinoma: Molecular and Pathological Features

  • Renato Franco
  • Anna Maria Anniciello
  • Gerardo Botti
  • Michele Caraglia
  • Amalia Luce
Part of the Current Clinical Pathology book series (CCPATH)


Basal cell carcinoma is the most common malignant tumour of humans, recording a progressive increase in incidence during the last decades. Basal cell carcinomas are locally destructive malignancies, mainly involving sun-exposed areas, such as head and neck skin. Basal cell carcinoma derives from basaloid epithelia located in the follicular bulges, and its development seems to be related to the deregulation of Hedgehog signalling pathway, primarily studied in the Gorlin-Goltz syndrome, characterised by a wide range of developmental abnormalities and predisposition to neoplasm, such as basal cell carcinomas. Basal cell carcinoma shows a clinical favourable behaviour, but some pathological features could suggest a more aggressive clinical course. In addition, the high incidence is responsible of a significant increasing workload for the health service, in relation to their treatment. Thus, novel therapy approaches have been developed in order to improve the treatment.


Basal Cell Carcinoma Nevoid Basal Cell Carcinoma Syndrome Basaloid Cell Superficial Basal Cell Carcinoma Nodular Basal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.




Aminolevulinic acid


Basal cell carcinoma






Methyl aminolevulinic


Mohs micrographic surgery


Photodynamic surgery


Sonic Hedgehog homologue






  1. 1.
    Garner KL, Rodney WN. Basal and squamous cell carcinoma. Prim Care. 2000;27(2):447–58.PubMedGoogle Scholar
  2. 2.
    Roewert-Huber J, Lange Asschnfeldt B, Stockfleth E, et al. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007;157 Suppl 2:47–51.PubMedGoogle Scholar
  3. 3.
    Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtypes. Br J Dermatol. 2002;147:41–7.PubMedGoogle Scholar
  4. 4.
    Skelton LA. The effective treatment of basal cell carcinoma. Br J Nurs. 2009;18:346–50.PubMedGoogle Scholar
  5. 5.
    Youssef KK, Van Keymeullen A, Lapounge G, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010;12:299–305.PubMedGoogle Scholar
  6. 6.
    Lear JT, Harvey I, de Berker D, Strange RC, Fryer AA. Basal cell carcinoma. J R Soc Med. 1998;91: 585–8.PubMedGoogle Scholar
  7. 7.
    Betti R, Inselvini E, Carducci M, Crosti C. Age and site prevalence of histologic subtypes of basal cell carcinomas. Int J Dermatol. 1995;34(3):174–6.PubMedGoogle Scholar
  8. 8.
    Fusaro RM, Gol RW. Histochemically demonstrable carbohydrates of appendageal tumor of the skin. II. Benign apocrine gland tumor. J Invest Dermatol. 1962;38:37.Google Scholar
  9. 9.
    Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63:8–18.PubMedGoogle Scholar
  10. 10.
    Bernard P, Dupuy A, Brun P, et al. Therapeutic modalities and economic assessment in the treatment of superficial basal cell carcinomas and multiple actinic keratoses by French dermatologists. Ann Dermatol Venereol. 2007;134(6–7):527–33.PubMedGoogle Scholar
  11. 11.
    Han J, Coldtz G, Hunter DJ. Risk factor for skin cancer: a nested casa control study within the Nurses Health study. Int J Epidemiol. 2006;35:1514–21.PubMedGoogle Scholar
  12. 12.
    Madan V, Hoban P, Stange RC, Fryer AA, Lear JT. Genetic and risk factor basal cell carcinoma. Br J Dermatol. 2006;154 Suppl 1:5–7.PubMedGoogle Scholar
  13. 13.
    Greinert R. Skin cancer: new marker for better prevention. Pathobiology. 2009;76:64–81.PubMedGoogle Scholar
  14. 14.
    Dipgen TL, Mattedi V. The epidemiology of skin cancer. Br J Dermatol. 2002;146 Suppl 61:1–6.Google Scholar
  15. 15.
    Bastiaens MT, Hoefnagel JJ, Bruin JA, et al. Differences in age, site, distribution and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol. 1998;110(6):880–4.PubMedGoogle Scholar
  16. 16.
    Vlajinac HD, Adanja BJ, Lazzar ZF, et al. Risk factors for basal cell carcinoma. Acta Oncol. 2000;39:611–6.PubMedGoogle Scholar
  17. 17.
    Gohara MA. Skin cancer in skins of color. J Drugs Dermatol. 2008;7:441–5.PubMedGoogle Scholar
  18. 18.
    Gloster Jr HM, Brodland DG. The epidemiology of skin cancer. Dermatol Surg. 1996;22:217–26.PubMedGoogle Scholar
  19. 19.
    Pennello G, Devesa S, Gail M. Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks. Cancer Epidemiol Biomarkers Prev. 2000;9(3):291–7.PubMedGoogle Scholar
  20. 20.
    Dessinotti C, Antoniou C, Katsambas A, et al. Basal cell carcinoma: what’s new under the sun. Photochem Photobiol. 2010;86:481–91.Google Scholar
  21. 21.
    Miller A, Tsao H. New insights into pigmentary pathways and skin cancer. Br J Dermatol. 2010;162:22–8.PubMedGoogle Scholar
  22. 22.
    Dessinotti C, Stratigos AJ, Rigopoupulos DAJ, et al. A review of genetic disorders of hypopigmentation: lessons learned from the biology of melanocytes. Exp Dermatol. 2009;18:741–9.Google Scholar
  23. 23.
    Hafner C, Landthaler M, Vogt T. Activation of the PI3K/AKT signalling pathway in non melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations. Exp Dermatol. 2010;19:e222–7.PubMedGoogle Scholar
  24. 24.
    Goldberg LH. Basal cell carcinoma. Lancet. 1996;347:663–7.PubMedGoogle Scholar
  25. 25.
    Hoban PR, Ramachandran S, Strange RC. Environment, phenotype and genetic: risk factors associated with BCC of the skin. Expert Rev Anticancer Ther. 2002;2:570–9.PubMedGoogle Scholar
  26. 26.
    Karagas MR, Nelson HH, Zencell MS, et al. Squamous and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology. 2007;18:776–84.PubMedGoogle Scholar
  27. 27.
    Cabrera HN, Gomez ML. Skin cancer induced by arsenic in the water. J Cutan Med Surg. 2003;7:106–11.PubMedGoogle Scholar
  28. 28.
    Ozyazgan I, Kontas O. Previous injuries or scars as risk factor for the development of basal cell carcinoma. Scand J Plast Reconstr Surg Hand Surg. 2004;38:11–5.PubMedGoogle Scholar
  29. 29.
    Spiewak R. Pesticides as cause of occupational skin disease in farmer. Ann Agric Environ Med. 2001;8:1–5.PubMedGoogle Scholar
  30. 30.
    Fredman DM, Sigurdson A, Dody MM, Mabuchi K, Linet MS. Risk of basal cell carcinoma in relation to alcohol intake and smoking. Cancer Epidemiol Biomarkers Prev. 2003;12:1540–3.Google Scholar
  31. 31.
    Sahl WJ, Glore S, Garrison P, Oakleaf K, Johnson SD. Basal cell carcinoma and lifestyle characteristics. Int J Dermatol. 1995;34:398–402.PubMedGoogle Scholar
  32. 32.
    Heffernan TP, Kawasumi M, Blasina A, Anderes K, Conney AH, Nghiem P. ATR-Chk1 pathway inhibition promotes apoptosis after UV treatment in primary human keratinocytes potential basis for the UV protective effects of caffeine. J Invest Dermatol. 2009;129:1805–15.PubMedGoogle Scholar
  33. 33.
    Lu YP, Lou YR, Xie JG, Peng QY, Zhou S, Lin Y, et al. Caffeine and caffeine sodium benzoate have a sunscreen effect, enhance UVB-induced apoptosis, and inhibit UVB-induced skin carcinogenesis in SKH-1 mice. Carcinogenesis. 2007;28:199–206.PubMedGoogle Scholar
  34. 34.
    Abel EL, Hendrix SO, McNeeley SG, Johnson KC, Rosenberg CA, Mossavar-Rahmani Y, et al. Daily coffee consumption and prevalence of nonmelanoma skin cancer in Caucasian women. Eur J Cancer Prev. 2007;16:446–52.PubMedGoogle Scholar
  35. 35.
    Martin RC, Edwards MJ, Cawte MJ, et al. Basosquamous carcinoma. Analysis of prognostic factors influencing recurrence. Cancer. 2000;88(6):1365–9. 136–42.PubMedGoogle Scholar
  36. 36.
    Richmond-Sinclair NM, Pandey N, Williams GM, Neale RE, van der Pols JC, Green AC. Clinical signs of photodamage are associated with basal cell carcinoma multiplicity and site: a 16 year longitudinal study. Int J Cancer. 2010;127:2622–9.PubMedGoogle Scholar
  37. 37.
    Hooper JE, Scott MP. Communicating with Hedgehogs. Nat Rev Mol Cell Biol. 2005;6:306–7.PubMedGoogle Scholar
  38. 38.
    Tang JY, So P-L, Epstein Jr EH. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol. 2007;224:257–64.PubMedGoogle Scholar
  39. 39.
    Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391:90–2.PubMedGoogle Scholar
  40. 40.
    Tojo M, Kiyosawa H, Iwatsuki K, et al. Expression of the GLI2 oncogene and its isoforms in human basal cell carcinoma. Br J Dermatol. 2003;148:892–7.PubMedGoogle Scholar
  41. 41.
    Hatta N, Hirano T, Kimura T, et al. Molecular diagnosis of basal cell carcinoma and other basaloid cell neoplasms of the skin by the quantification of GLI1 transcript levels. J Cutan Pathol. 2005;32:131–6.PubMedGoogle Scholar
  42. 42.
    Regl G, Kasper M, Schnidar H, et al. The zinc-finger transcription factor GLI2 antagonizes contact inhibition and differentiation of human epidermal cells. Oncogene. 2004;23:1263–74.PubMedGoogle Scholar
  43. 43.
    Johnson R, Rothman A, Xie J, et al. Human homolog of patched a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668–71.PubMedGoogle Scholar
  44. 44.
    Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8:743–54.PubMedGoogle Scholar
  45. 45.
    Wang GY, Wang J, Mancianti ML, Epstein Jr EH. Basal cell carcinoma arise from hair follicle stem cells in PTCH1+/− mice. Cancer Cell. 2011;19:114–24.PubMedGoogle Scholar
  46. 46.
    Barnes EA, Kong M, Ollendorff V, Donoghue DJ. Patched1 interacts with cyclin B1 to regulate cell cycle progression. EMBO J. 2001;20:2214–23.PubMedGoogle Scholar
  47. 47.
    Wetmore C, Eberhart DE, Currann T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 2001;61:513–6.PubMedGoogle Scholar
  48. 48.
    Grachtchouk M, Pero J, Yang SH, et al. Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. J Clin Invest. 2011;121:1768–81.PubMedGoogle Scholar
  49. 49.
    Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1998;58:1798–803.PubMedGoogle Scholar
  50. 50.
    Reifenberger J, Wolter M, Knobbe SB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005;152:43–51.PubMedGoogle Scholar
  51. 51.
    Crowson AN, Magro CM, Kadin M, et al. Differential expression of Bcl-2 oncogene in human basal cell carcinoma. Hum Pathol. 1996;27:355–9.PubMedGoogle Scholar
  52. 52.
    Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol. 2006;19:S127–47.PubMedGoogle Scholar
  53. 53.
    Bavinck JNB, de Boer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol. 1993;129:242–9. 91.PubMedGoogle Scholar
  54. 54.
    Rady RL, Yen A, Rollefson JL, et al. Herpes virus-like DNA sequences in non-Kaposi’s sarcoma skin lesions of transplant patients. Lancet. 1995;345:1339–40.PubMedGoogle Scholar
  55. 55.
    Sitz KV, Keppen M, Johnson DF. Metastatic basal cell carcinoma in acquired immunodeficiency syndrome related complex. JAMA. 1987;257:340–3.PubMedGoogle Scholar
  56. 56.
    Oram Y, Orengo I, Griego RD, et al. Histologic patterns of basal cell carcinoma based upon patient immunostatus. Dermatol Surg. 1995;21:611–4.PubMedGoogle Scholar
  57. 57.
    Aoyagi S, Nouri K. Difference between pigmented and nonpigmented basal cell carcinoma treated with Mohs micrographic surgery. Dermatol Surg. 2006;32:1375–9.PubMedGoogle Scholar
  58. 58.
    Betti R, Gualandri L, Cerri A, et al. Clinical features and histologic pattern analysis of pigmented basal cell carcinoma in an Italian population. J Dermatol. 1998;25:691–4.PubMedGoogle Scholar
  59. 59.
    Mc Nuth NS. Ultrastructural comparison of the interface between epithelium and stroma in basal cell and control human skin. Lab Invest. 1976;35:132.Google Scholar
  60. 60.
    Farmer ER, Helwing EB. Metastatic basal cell carcinoma: a clinicopathologic study of seventeen cases. Cancer. 1980;46:748.PubMedGoogle Scholar
  61. 61.
    Howell JB. The basal cell nevus. Arch Dermatol. 1959;79:67.Google Scholar
  62. 62.
    Viksnis P, Berlin A. Follicular atrophoderma and basal cell carcinoma. Arch Dermatol. 1977;113:948.Google Scholar
  63. 63.
    Pilosila M, Kiistala R, Niemi KM, et al. The Bazex syndrome: follicular atrophoderma with multiple basal cell carcinoma, hypotricosis and hypohidrosis. Clin Exp Dermatol. 1981;89:598.Google Scholar
  64. 64.
    Mongomery H. Basal squamous cell epithelioma. Arch Dermatol Syph. 1928;18:50.Google Scholar
  65. 65.
    Borel DM. Cutaneous basosquamous carcinoma: review of the literature and report of 35 cases. Arch Pathol. 1973;95:293.PubMedGoogle Scholar
  66. 66.
    Foot NC. Adnexal carcinoma of the skin. Am J Pathol. 1947;23:1.PubMedGoogle Scholar
  67. 67.
    Kato N, Ueno H. Infundibulocystic basal cell carcinoma. Am J Dermatopathol. 1993;15:265–7.PubMedGoogle Scholar
  68. 68.
    Ali F, Brown A, Gottwald L, et al. Basal cell carcinoma with matrical differentiation in a transplant patient: a case report and review of the literature. J Cutan Pathol. 2005;32:445–8.PubMedGoogle Scholar
  69. 69.
    Elston DM, Bergfeld WF, Petroff N. Basal cell carcinoma with monster cells. J Cutan Pathol. 1993;20:70–3.PubMedGoogle Scholar
  70. 70.
    Hanke CW, Temofeew RK. Basal cell carcinoma with eccrine differentiation (eccrine epithelioma). J Dermatol Surg Oncol. 1986;12:820–4.PubMedGoogle Scholar
  71. 71.
    Misago N, Satoh T, Narisawa Y. Basal cell carcinoma with ductal and glandular differentiation: a clinicopathological and immunohistochemical study of 10 cases. Eur J Dermatol. 2004;14:383–7.PubMedGoogle Scholar
  72. 72.
    Misago N, Mihara I, Ansai S-I, et al. Sebaceoma and related neoplasms with sebaceous differentiation. Am J Dermatopathol. 2002;24:294–304.PubMedGoogle Scholar
  73. 73.
    Pinkus H. Premalignant fibroepithelial tumors of the skin. Arch Dermatol Syph. 1953;67:598.Google Scholar
  74. 74.
    Pinkus H. Epithelial and fibroepithelial tumors. Arch Dermatol. 1965;91:24–37.PubMedGoogle Scholar
  75. 75.
    Lerchin E, Rahbari H. Adamantinoid basal cell epithelioma. Arch Dermatol. 1975;111:1064.Google Scholar
  76. 76.
    Barr RJ, Graham JH. Granular basal cell carcinoma. Arch Dermatol. 1979;115:1064.PubMedGoogle Scholar
  77. 77.
    Mrak RE, Baker GF. Granular basal cell carcinoma. J Cutan Pathol. 1987;14:37.PubMedGoogle Scholar
  78. 78.
    Barnadas MA, Freeman RG. Clear cell basal epithelioma. J Cutan Pathol. 1988;15:1.PubMedGoogle Scholar
  79. 79.
    Dixon AY, Lee SH, Mc Gragor DH. Factor predictive of recurrence of basal cell carcinoma. Am J Dermatopathol. 1989;11:222.PubMedGoogle Scholar
  80. 80.
    Griffiths RW. Audit of histologically incompletely excised basal cell carcinomas: recommendations for management by re-excision. Br J Plast Surg. 1999;52:24–8.PubMedGoogle Scholar
  81. 81.
    Wilson AW, Howsam G, Santhanam V, et al. Surgical management of incompletely excised basal cell carcinomas of the head and neck. Br J Oral Maxillofac Surg. 2004;42:311–4.PubMedGoogle Scholar
  82. 82.
    De Silva SP, Dellon AL. Recurrence rate of positive margin basal cell carcinoma: results of a five-year prospective study. J Surg Oncol. 1985;28:72–4.PubMedGoogle Scholar
  83. 83.
    Smith V, Walton S. Treatment of facial Basal cell carcinoma: a review. J Skin Cancer. 2011;2011:380371.PubMedGoogle Scholar
  84. 84.
    Malhotra R, Wennberg AM, Larko O, Stenquist B. Five-year results of Mohs’ micrographic surgery for aggressive facial basal cell carcinoma in Sweden. Acta Derm Venereol. 1999;79:370–2.Google Scholar
  85. 85.
    Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology. 2004;111:631–6.PubMedGoogle Scholar
  86. 86.
    Wennberg M, Lark¨o O, Stenquist B. Five-year results of Mohs’ micrographic surgery for aggressive facial basal cell carcinoma in Sweden. Acta Derm Venereol. 1999;79:370–2.PubMedGoogle Scholar
  87. 87.
    Leibovitch SC, Huilgol Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol. 2005;53:452–7.PubMedGoogle Scholar
  88. 88.
    Rowe DE, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976–90.PubMedGoogle Scholar
  89. 89.
    Kopf W, Bart RS, Schrager D. Curettage electrodesiccation treatment of basal cell carcinomas. Arch Dermatol. 1977;113:439–43.PubMedGoogle Scholar
  90. 90.
    Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg. 2004;30:297–300.PubMedGoogle Scholar
  91. 91.
    Rowe DE, Carroll RJ, Day CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. Dermatol Surg Oncol. 1989;15:315–28.Google Scholar
  92. 92.
    Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722–33.PubMedGoogle Scholar
  93. 93.
    Gollnick H, Barona C, Fra RGJ, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5 % cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol. 2005;15:374–81.PubMedGoogle Scholar
  94. 94.
    Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008;159:1245–66.PubMedGoogle Scholar
  95. 95.
    Testori A, Tosti G, Martinoli C, et al. Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther. 2010;23:651–61.PubMedGoogle Scholar
  96. 96.
    Xie J, Aszterbaum M, Zhang X, et al. A role of PDGFRα in basal cell carcinoma proliferation. Proc Natl Acad Sci U S A. 2001;98:9255–9.PubMedGoogle Scholar
  97. 97.
    Carneiro BA, Watkin WG, Mehta UK, Brockstein BE. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 2006;24:396–400.PubMedGoogle Scholar
  98. 98.
    Binns W, Jame LF, Shupe JL, Everett G. A congenital cyclopian-type malformation in lambs induced by maternal ingestion of a range plant. Veratrum californicum. Am J Vet Res. 1963;24:1164–75.PubMedGoogle Scholar
  99. 99.
    Tabs S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol. 2004;14:96–102.PubMedGoogle Scholar
  100. 100.
    Cooper MK, Porte JA, Young KE. Beachy Teratogen-mediated inhibition of target tissue response to Shh signaling. Science. 1998;280:1603–7.PubMedGoogle Scholar
  101. 101.
    Incardona JP, Gaffield W, Kapur RP, Roelink H. The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development. 1998;125:3553–62.PubMedGoogle Scholar
  102. 102.
    Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002;16:2743–8.PubMedGoogle Scholar
  103. 103.
    Chen JK, Taipale J, Cooper MK, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 2000;406:1005–9.PubMedGoogle Scholar
  104. 104.
    Van Hoff DD, et al. Efficacy data of GDC-0449, a systemic Hedgehog (Hh) pathway antagonist, in a first-in-human, first-in-class, phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients. Proceedings of the 99th annual meeting of the American Association for Cancer Research. 2008; abstract LB-138.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Renato Franco
    • 1
  • Anna Maria Anniciello
    • 1
  • Gerardo Botti
    • 1
  • Michele Caraglia
    • 2
  • Amalia Luce
    • 2
  1. 1.Pathology UnitNational Institute of Tumours Fondazione “G. Pascale”NaplesItaly
  2. 2.Department of Biochemistry and BiophysicsSecond University of NaplesNaplesItaly

Personalised recommendations